|
US2008220074A1
|
|
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
|
US2008317843A1
|
|
Nanoparticulate formulations of modafinil
|
|
US2007122481A1
|
|
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
|
US2010247636A1
|
|
Nanoparticulate and controlled release compositions comprising nilvadipine
|
|
US2007160675A1
|
|
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
|
WO2007037790A2
|
|
Modified release famciclovir compositions
|
|
US2008118556A1
|
|
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
|
|
WO2008079102A1
|
|
Modified release loxoprofen compositions
|
|
US2006240105A1
|
|
Multiparticulate modified release composition
|
|
WO2006063078A2
|
|
Topiramate pharmaceuticals composition
|
|
WO2004034959A2
|
|
Multiparticulate modified release composition comprising beraprost
|
|
WO03039561A1
|
|
Pharmaceutical composition
|
|
AU2002330692A1
|
|
Delivery of a bioactive material
|
|
CA2451741A1
|
|
Peyers's patch and/or m-celle targeting ligands
|
|
EP1419252A2
|
|
Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
|
|
GB0101966D0
|
|
Pharmaceutical formulations
|
|
GB0028575D0
|
|
Oral pharmaceutical compositions containing cyclodextrins
|
|
US6780846B1
|
|
Membrane translocating peptide drug delivery system
|
|
AU6715600A
|
|
Pharmaceutical formulations
|
|
US6521737B1
|
|
Peptides which enhance transport across tissues and methods of identifying and using the same
|
